Analgin-UBF - instructions for use, dose, side effects, contraindications

Metamizole sodium - an analgesic non-narcotic agent, a derivative of pyrazolone, nonselectively blocks cyclooxygenase and reduces the formation of prostaglandins from arachidonic acid.

It prevents painful extra- and proprioceptive pulses along the Gaull and Burdach beams, raises the threshold of excitability of thalamic centers of pain sensitivity, increases heat transfer.

A distinctive feature is the slight severity of the anti-inflammatory effect, which causes a weak effect on water-salt metabolism (retention of sodium and water ions) and the mucous membrane of the gastrointestinal tract. Has analgesic, antipyretic and some spasmolytic (with respect to the smooth muscles of the urinary and bile ducts) action.

The action develops 20-40 minutes after ingestion and reaches a maximum after 2 hours.

Pharmacokinetics:

Good and quickly absorbed into the gastrointestinal tract.

In the intestinal wall it hydrolyzes with the formation of an active metabolite. Unchanged metamizol sodium in the blood is absent (only after intravenous administration, its insignificant concentration is detected in the plasma).

The association of the active metabolite with plasma proteins is 50-60%.

Metabolized in the liver, excreted by the kidneys.

In therapeutic concentrations penetrates into breast milk.

Indications:

Feverish syndrome (infectious and inflammatory diseases, insect bites - mosquitoes, bees, gadflies, etc., posttransfusion complications).

Pain syndrome (mild to moderate): including neuralgia, myalgia, arthralgia, biliary colic, intestinal colic, renal colic, trauma, burns, decompression sickness, shingles, orchitis, sciatica, myositis, postoperative pain syndrome, headache, toothache, algodismenorea.

Contraindications:

Hypersensitivity to the components of the drug, oppression of hematopoiesis (agranulocytosis, cytostatic or infectious neutropenia), hepatic and / or renal failure, hereditary hemolytic anemia associated with deficiency of glucose-6-phosphate dehydrogenase; complete or incomplete combination of bronchial asthma, recurrent nasal polyposis and paranasal sinuses and intolerance to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (including in history); anemia, and leukopenia. Children up to 8 years.

Carefully:

Kidney disease (pyelonephritis, glomerulonephritis - including in the history), alcoholism.

Pregnancy and lactation:

The drug is contraindicated in pregnancy, during lactation.

Dosing and Administration:

Tablets are taken after meals, washed down with a small amount of water.

Adults-250-500 mg 2-3 times a day. The maximum single dose is 1 g, the daily dose is 3 g. Single doses for children 8-14 years, adolescents over 15 years - 250-300 mg, the frequency of reception is 2-3 times a day.

Do not use (without consulting a doctor) for more than 3 days when prescribed as an antipyretic and for more than 5 days - as an anesthetic.

Side effects:

From the urinary system: a violation of kidney function, oliguria, anuria, proteinuria, interstitial nephritis, urine staining in red.

Allergic reactions: urticaria (including conjunctiva and mucous membranes of the nasopharynx), angioedema, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), bronchospastic syndrome, anaphylactic shock.

On the part of the organs of hematopoiesis: agranulocytosis, leukopenia, thrombocytopenia.

Other: lowering blood pressure.

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, inform the doctor about it.

Overdose:

With prolonged use of the drug (more than 7 days) in large doses, the following symptoms of overdose may occur: nausea, vomiting, gastralgia, oliguria, hypothermia, lowering of arterial pressure, tachycardia, dyspnea, tinnitus, drowsiness, delirium, impaired consciousness, acute agranulocytosis, hemorrhagic syndrome, acute renal and / or hepatic insufficiency, convulsions, paralysis of the respiratory musculature.

Treatment: gastric lavage, take saline laxatives, Activated carbon. In the conditions of the medical institution - conducting forced diuresis, hemodialysis, with the development of convulsive syndrome - intravenous diazepam and high-speed barbiturates.

Interaction:

The simultaneous use of metamizole sodium with other non-narcotic analgesics may lead to a mutual enhancement of toxic effects.

Tricyclic antidepressants, contraceptives for oral administration and allopurinol disrupt the metabolism of metamizole sodium in the liver and increase its toxicity.

Phenylbutazone, barbiturates and other inducers of microsomal liver enzymes with simultaneous use reduce the effectiveness of metamizole sodium.

Metamizole sodium enhances the effects of alcohol-containing beverages.

Simultaneous use of metamizole sodium with cyclosporine reduces the concentration of the latter in the blood.

Radiocontrast agents, colloidal blood substitutes and penicillin should not be used during treatment with metamizole sodium.

Metamizole sodium, displacing from the connection with plasma proteins, oral hypoglycemic drugs, indirect anticoagulants, glucocorticosteroids and indomethacin, increases their activity.

Thiamazole and sarcolysin increase the risk of developing leukopenia.

The effect is enhanced codeine, H2-histamine receptor blockers and propranolol (slows inactivation).

Sedatives and tranquilizers increase the analgesic effect of metamizole sodium.

Myelotoxic drugs increase the manifestation of hematotoxicity of the drug.

Special instructions:

In the treatment of patients receiving cytotoxic drugs, metamizole sodium should be administered only under medical supervision.

Intolerance is very rare, but the threat of anaphylactic shock after intravenous administration of the drug is relatively higher,than after taking the drug inside.

Patients with bronchial asthma and hay fever may develop reactions of hypersensitivity.

Against the background of taking metamizole sodium, the development of agranulocytosis is possible, in connection with which, when an unmotivated rise in temperature, chills, sore throats, difficulty swallowing, stomatitis, as well as in the development of phenomena of vaginitis or proctitis, immediate withdrawal of the drug is necessary. With prolonged use (more than 7 days), you need to monitor the picture of peripheral blood.

It is inadmissible to use to relieve acute pain in the abdomen (until the cause is clarified). Special caution is required when prescribing alcoholism to patients.

Effect on the ability to drive transp. cf. and fur:When administered orally at therapeutic doses, Analgin-UBF does not affect the ability to drive and perform work requiring increased attention.

Form release / dosage:

Tablets 500 mg.

Packaging:

For 10 tablets in a contour non-cellular package of paper with a polymer coating.

For 10 tablets in a contour mesh package made of a polyvinylchloride film and aluminum foil or paper with a polymeric coating.

By 20, 25, 30,40, 50, 60 tablets in cans of polymeric.

Each bank, or 1, 2, 3, 4, 5 contour non-jammed packages, or contour mesh packages together with the instruction for use, is placed in a bundle.

Banks polymeric, or contour non-cellular packages, or contour mesh packages with an equal number of instructions for use are placed in a bag of polyethylene film or a cardboard box.

Storage conditions:

In dry, dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

5 years.

Do not use after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:P N002524 / 01-2003

Date of registration:29.07.2008 / 12.04.2012

Expiration Date:Unlimited

The owner of the registration certificate:URALBIOFARM, OJSC URALBIOFARM, OJSC Russia

Manufacturer: & nbsp

URALBIOFARM, OJSC Russia

Representation: & nbspURALBIOFARM, OJSCURALBIOFARM, OJSCRussia

Information update date: & nbsp27.08.2017

Illustrated instructions

Instructions

Analgin-UBF (Analgin-UBF)